Crispr Therapeutics: Poised For A Major Turnaround

CRISPR Therapeutics (NASDAQ: CRSP ) is the market leader in transformative therapies incorporating CRISPR/Cas9 biotechnology, and their 9-year ongoing partnership with Vertex Pharmaceuticals ( VRTX ) brings great promise. Most recently, both companies received FDA (December 2023) and EMA (February 2024) approvals for Casgevy, the I have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the p ...